In total, 1,797 patients (56.5%) had established CV disease without CKD, 354 patients (11.1%) had CKD only, and 544 patients (17.1%) had both CV disease and CKD
Trials with liraglutide 1.8 mg have shown weight loss up to 3.6% (3.3 kg) at 26 weeks and 4.7% (5.0 kg) at 56 weeks in subjects with T2D (171173), while trials with liraglutide 3.0 mg have shown weight loss of between 7.9% (8.9 kg) and 8.2% (7.3 kg) at 56 weeks in subjects with obesity (173175)
This helps your healthcare provider monitor your treatment and make any necessary adjustments
In roGFP, two surface-exposed cysteines were introduced into the -barrel (-sheet reach region) of standard GFP at positions 147 and 204
It is geared more toward users who are focused on sustained weight loss, rather than those looking to shed pounds for a short-term goal, such as an upcoming event